CytoDyn Inc (OTCPK:CYDY)
$ 0.1351 -0.00065 (-0.48%) Market Cap: 143.01 Mil Enterprise Value: 172.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 32/100

Cytodyn Inc at This Week on RedChip TV: 3 Stocks Positioned for Upside in 2020 Transcript

Feb 19, 2020 / NTS GMT
Release Date Price: $1.07 (+2.88%)
Jon Cunningham
RedChip Companies - Moderator

Hello, I'm Jon Cunningham. Welcome to the RedChip Money Report. For those of you new to the show, RedChip is an investor relations, media and research firm focused on emerging growth companies. Our unique platform combines global multimedia with traditional investor relations reaching investors around the world.

Now today's features interviews with executives of three public companies. First, you'll see an interview with CEO of CytoDyn, stock symbol CYDY on the OTCQB. CytoDyn is a late-stage biotechnology company with near-term commercialization of an HIV combination therapy that met its primary endpoints in its recently completed Phase 3 trial. The company is using the same drug to target immunology and cancer indications and just filed its Phase 2 protocol for a basket trial that's targeting 22 solid tumor cancers. Learn more from the CEO later in the show.

The next interview will be with the CEO of Seeing Machines, stock symbol SEEMF on the OTC and SEE on the London Stock Exchange. Seeing Machines is an advanced computer technology company

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot